

Supplementary Data to the article “The prognostic value of mean platelet volume in patients with coronary artery disease: a systematic review with meta-analyses.”

Content

[Supplementary search strategy](#)

[Supplementary Table 1. Additional sources.](#)

[Supplementary Table 2. A list of some excluded studies with reasons for exclusion.](#)

[Supplementary Table 3. Baseline features of the included studies](#)

[Supplementary Table 4. Leave-one out sensitivity analyses.](#)

[Supplementary Table 5. Subgroup analyses.](#)

[Supplementary Table 6. Meta-regression analysis.](#)

[Supplementary Figures](#)

[Supplementary Figure S1. All ischemic heart disease patients. Additional analyses for long-term mortality with MPV as a continuous variable and hazard ratios as effect estimates.](#)

[Supplementary Figure S2. All ischemic heart disease patients. Analyses for long-term mortality with MPV treated as a categorical variable and hazard ratios as effect estimates.](#)

[Supplementary Figure S3. All ischemic heart disease patients. Analyses for long-term major cardiovascular events with MPV treated as a continuous variable and hazard ratios as effect estimates.](#)

[Supplementary Figure S4. All ischemic heart disease patients. Additional analyses for long-term major cardiovascular events with MPV treated as a continuous variable and hazard ratios as effect estimates.](#)

[Supplementary Figure S5. All ischemic heart disease patients. Analyses for long-term major cardiovascular events with MPV treated as a categorical variable and hazard ratios as effect estimates.](#)

[Supplementary Figure S6. All ischemic heart disease patients. Additional analyses for long-term major cardiovascular events with MPV treated as a categorical variable and hazard ratios as effect estimates.](#)

[Supplementary Figure S7. All ischemic heart disease patients. Analyses for long-term major cardiovascular events with MPV treated as a categorical variable and odds ratios as effect estimates.](#)

[Supplementary Figure S8. All ischemic heart disease patients. Analyses for long-term mortality with MPV treated as a categorical variable and odds ratios as effect estimates.](#)

[Supplementary Figure S9. All ischemic heart disease patients. Analyses for one-month mortality with MPV treated as a continuous variable and hazard ratios as effect estimates.](#)

[Supplementary Figure S10. All ischemic heart disease patients. Analyses for one-month mortality with MPV treated as a categorical variable and odds ratios as effect estimates.](#)

[Supplementary Figure S11. All ischemic heart disease patients. Analyses for one-month major adverse cardiovascular events with MPV treated as a categorical variable and odds ratios as effect estimates.](#)

[Supplementary Figure S12. All ischemic heart disease patients. Analyses for inhospital mortality with MPV treated as a categorical variable and odds ratios as effect estimates.](#)

[Supplementary Figure S13. All ischemic heart disease patients. Analyses for inhospital major adverse cardiovascular events with MPV treated as a categorical variable and odds ratios as effect estimates.](#)

[Supplementary Figure S14. Patients treated with percutaneous coronary intervention.](#)

Additional analyses for long-term mortality with MPV treated as a continuous variable and hazard ratios as effect estimates.

Supplementary Figure S15. Patients treated with percutaneous coronary intervention. Analyses for long-term major adverse cardiovascular events with MPV treated as a continuous variable and hazard ratios as effect estimates.

Supplementary Figure S16. Patients treated with percutaneous coronary intervention. Analyses for long-term major adverse cardiovascular events with MPV treated as a categorical variable and hazard ratios as effect estimates.

Supplementary Figure S17. Patients treated with percutaneous coronary intervention. Analyses for long-term major adverse cardiovascular events with MPV treated as a categorical variable and odds ratios as effect estimates.

Supplementary Figure S18. Patients treated with percutaneous coronary intervention. Analyses for one-month mortality with MPV treated as a continuous variable and hazard ratios as effect estimates.

Supplementary Figure S19. Patients treated with percutaneous coronary intervention. Analyses for inhospital major adverse cardiovascular events with MPV treated as a categorical variable and odds ratios as effect estimates.

Supplementary Figure S20. Patients with acute coronary syndrome. Analyses for long-term mortality with MPV treated as a continuous variable and hazard ratios as effect estimates.

Supplementary Figure S21. Patients with acute coronary syndrome. Additional analyses for long-term mortality with MPV treated as a continuous variable and hazard ratios as effect estimates.

Supplementary Figure S22. Patients with acute coronary syndrome. Analyses for long-term mortality with MPV treated as a categorical variable and hazard ratios as effect estimates.

Supplementary Figure S23. Patients with acute coronary syndrome. Analyses for long-term major adverse cardiovascular events with MPV treated as a continuous variable and hazard ratios as effect estimates.

Supplementary Figure S24. Patients with acute coronary syndrome. Additional analyses for long-term major adverse cardiovascular events with MPV treated as a continuous variable and hazard ratios as effect estimates.

Supplementary Figure S25. Patients with acute coronary syndrome. Analyses for long-term major adverse cardiovascular events with MPV treated as a categorical variable and hazard ratios as effect estimates.

Supplementary Figure S26. Patients with acute coronary syndrome. Additional analyses for long-term major adverse cardiovascular events with MPV treated as a categorical variable and hazard ratios as effect estimates.

Supplementary Figure S27. Patients with acute coronary syndrome. Analyses for long-term major adverse cardiovascular events with MPV treated as a categorical variable and odds ratios as effect estimates.

Supplementary Figure S28. Patients with acute coronary syndrome. Analyses for one-month mortality with MPV treated as a continuous variable and hazard ratios as effect estimates.

Supplementary Figure S29. Patients with acute coronary syndrome. Analyses for one-month mortality with MPV treated as a categorical variable and odds ratios as effect estimates.

Supplementary Figure S30. Patients with acute coronary syndrome. Analyses for inhospital mortality with MPV treated as a categorical variable and odds ratios as effect estimates.

Supplementary Figure S31. Patients with acute coronary syndrome. Analyses for inhospital major adverse cardiovascular events with MPV treated as a categorical variable and odds ratios as effect estimates.

Supplementary Figure S32. Patients with acute coronary syndrome. Additional analyses for inhospital major adverse cardiovascular events with MPV treated as a categorical variable and odds ratios as effect estimates.

Supplementary Figure S33. Patients with stable coronary artery disease. Analyses for long-term mortality with MPV treated as a continuous variable and hazard ratios as effect estimates.

Supplementary Figure S34. Patients with stable coronary artery disease. Analyses for long-term major adverse cardiovascular events with MPV treated as a continuous variable and hazard ratios as effect estimates.

Supplementary Figure S35. Patients with stable coronary artery disease. Analyses for long-term major adverse cardiovascular events with MPV treated as a categorical variable and odds ratios as effect estimates.

Supplementary search strategy

Database: PubMed

Last search date: 18 Dec 2023

Number of items: 5509

#1 – Patient - (("Acute Coronary Syndrome" [MeSH Terms] OR "Coronary Artery Disease" [MeSH Terms] OR "Myocardial Infarction" [MeSH Terms] OR "Percutaneous Coronary Intervention" [MeSH Terms] OR "ST Elevation Myocardial Infarction" [MeSH Terms] OR "Non-ST Elevated Myocardial Infarction" [MeSH Terms] OR "angioplasty, balloon, coronary" [MeSH Terms] OR "Drug-Eluting Stents" [MeSH Terms] OR "Coronary Thrombosis" [MeSH Terms] OR "angina, unstable" [MeSH Terms] OR "angina pectoris, variant" [MeSH Terms] OR "Myocardial Ischemia" [MeSH Terms] OR "Coronary Care Units" [MeSH Terms] OR "Coronary Stenosis" [MeSH Terms] OR "acute coronary syndrom*" [Title/Abstract] OR "coronary artery disease*" [Title/Abstract] OR "Myocardial Infarction" [Title/Abstract] OR "ischemic heart disease*" [Title/Abstract] OR "ischaemic heart disease*" [Title/Abstract] OR "percutaneous coronary intervention*" [Title/Abstract] OR "primary angioplasty" [Title/Abstract] OR "Drug-Eluting Stents" [Title/Abstract] OR "Drug-Eluted Stents" [Title/Abstract] OR "STEMI" [Title/Abstract] OR "unstable angina" [Title/Abstract] OR "bare metal stent*" [Title/Abstract] OR "myocardial infarction with st" [Title/Abstract] OR "myocardial infarction without st" [Title/Abstract] OR "coronary angioplast*" [Title/Abstract] OR "coronary stent*" [Title/Abstract])

#2 – Exposure - ("Mean Platelet Volume" [MeSH Terms] OR "Blood Platelets" [MeSH Terms] OR "Platelet Count" [MeSH Terms] OR "Blood Cell Count" [MeSH Terms] OR "Thrombocytopenia" [MeSH Terms] OR "Thrombocytosis" [MeSH Terms] OR "Mean Platelet Volume" [Title/Abstract] OR "blood platelet*" [Title/Abstract] OR "platelet count*" [Title/Abstract] OR "platelet volum*" [Title/Abstract] OR "thrombocytopen*" [Title/Abstract] OR "Thrombocytosis" [Title/Abstract] OR "platelet indic*" [Title/Abstract] OR "platelet parameter*" [Title/Abstract] OR "platelet index*" [Title/Abstract] OR "large platelet*" [Title/Abstract] OR "larger platelet*" [Title/Abstract] OR "platelet size" [Title/Abstract] OR "complete blood count*" [Title/Abstract] OR "hematological parameter*" [Title/Abstract] OR "haematological parameter*" [Title/Abstract] OR "hematological marker*" [Title/Abstract] OR "haematological marker*" [Title/Abstract] OR "platelet marker*" [Title/Abstract] OR "hematological indic*" [Title/Abstract] OR "haematological indic*" [Title/Abstract] OR "hematological index*" [Title/Abstract] OR "haematological index*" [Title/Abstract] OR "platelet number*" [Title/Abstract]))

#3 – Outcome - ("Mortality" [MeSH Terms] OR "Hospital Mortality" [MeSH Terms] OR "Prognosis" [MeSH Terms] OR "Biomarkers" [MeSH Terms] OR "Follow-Up Studies" [MeSH Terms] OR "Kaplan-Meier Estimate" [MeSH Terms] OR "Proportional Hazards Models" [MeSH Terms] OR "Odds Ratio" [MeSH Terms] OR "Predictive Value of Tests" [MeSH Terms] OR "Prospective Studies" [MeSH Terms] OR "Cohort Studies" [MeSH Terms] OR "Risk Assessment" [MeSH Terms] OR "Risk Factors" [MeSH Terms] OR "Heart Disease Risk Factors" [MeSH Terms] OR "Cardiometabolic Risk Factors" [MeSH Terms] OR "ROC Curve" [MeSH Terms] OR "Clinical Decision Rules" [MeSH Terms] OR "Survival Analysis" [MeSH Terms] OR "Heart Arrest" [MeSH Terms] OR "Area Under Curve" [MeSH Terms] OR "Cause of Death" [MeSH Terms] OR "coronary thrombosis/prevention and control" [MeSH Terms] OR "Survival Rate" [MeSH Terms] OR "Coronary Restenosis" [MeSH Terms] OR "long-term prognos*" [Title/Abstract] OR "long-term outcom*" [Title/Abstract] OR "long-term surviv*" [Title/Abstract] OR "long-term adverse outcom*" [Title/Abstract] OR "long term prognos*" [Title/Abstract] OR "long term outcom*" [Title/Abstract] OR "long term adverse outcom*" [Title/Abstract] OR "long term surviv*" [Title/Abstract] OR "short-term prognos*" [Title/Abstract] OR "short-term outcom*" [Title/Abstract] OR "short-term adverse

outcom*"[Title/Abstract] OR "short-term surviv*"[Title/Abstract] OR "short term prognos*"[Title/Abstract] OR "short term outcom*"[Title/Abstract] OR "short term adverse outcom*"[Title/Abstract] OR "short term surviv*"[Title/Abstract] OR "cardiovascular outcom*"[Title/Abstract] OR "cardio-vascular outcom*"[Title/Abstract] OR "cardiac outcom*"[Title/Abstract] OR "cerebral outcom*"[Title/Abstract] OR "cerebrovascular outcom*"[Title/Abstract] OR "thrombotic outcom*"[Title/Abstract] OR "ischemic outcom*"[Title/Abstract] OR "ischaemic outcom*"[Title/Abstract] OR "cardiovascular endpoint*"[Title/Abstract] OR "cardiac endpoint*"[Title/Abstract] OR "cerebrovascular endpoint*"[Title/Abstract] OR "thrombotic endpoint*"[Title/Abstract] OR "ischaemic endpoint*"[Title/Abstract] OR "ischemic endpoint*"[Title/Abstract] OR "cardiovascular end point*"[Title/Abstract] OR "cardiac end point*"[Title/Abstract] OR "cerebrovascular endpoint*"[Title/Abstract] OR "cerebrovascular end point*"[Title/Abstract] OR "ischaemic end point*"[Title/Abstract] OR "cardiovascular end-point*"[Title/Abstract] OR "cardiac end-point*"[Title/Abstract] OR "cerebrovascular end-point*"[Title/Abstract] OR "ischaemic end-point*"[Title/Abstract] OR "ischemic end-point*"[Title/Abstract] OR "cardiovascular complication*"[Title/Abstract] OR "cardio-vascular complication*"[Title/Abstract] OR "cardiac complication*"[Title/Abstract] OR "cerebral complication*"[Title/Abstract] OR "cerebrovascular complication*"[Title/Abstract] OR "cerebro-vascular complication*"[Title/Abstract] OR "thrombotic complication*"[Title/Abstract] OR "ischaemic complication*"[Title/Abstract] OR "ischemic complication*"[Title/Abstract] OR "adverse cardiac event*"[Title/Abstract] OR "adverse cardiovascular event*"[Title/Abstract] OR "adverse cardio-vascular event*"[Title/Abstract] OR "major adverse cardiovascular event*"[Title/Abstract] OR MACCE[Title/Abstract] OR "cerebral event"[Title/Abstract] OR "cerebrovascular event"[Title/Abstract] OR "reinfarction"[Title/Abstract] OR "re-infarction"[Title/Abstract] OR "Coronary Restenosis"[Title/Abstract] OR "coronary re-stenosis"[Title/Abstract] OR "stent thrombosis"[Title/Abstract] OR "area under curve*"[Title/Abstract] OR "survival analys*"[Title/Abstract] OR "target vessel revascularization"[Title/Abstract] OR "target vessel revascularisation"[Title/Abstract] OR "target lesion revascularization"[Title/Abstract] OR "target lesion revascularisation"[Title/Abstract] OR "kaplan meir curve*"[Title/Abstract] OR "kaplan meir analys*"[Title/Abstract] OR "kaplan meir surviv*"[Title/Abstract] OR "proportional hazard model*"[Title/Abstract] OR "roc curve*"[Title/Abstract] OR "cardiovascular death"[Title/Abstract] OR "cardio-vascular death"[Title/Abstract] OR "cardiac death"[Title/Abstract] OR "cardiovascular risk"[Title/Abstract] OR "cardio-vascular risk"[Title/Abstract] OR "cerebrovascular risk"[Title/Abstract] OR "atherothrombotic risk"[Title/Abstract] OR "thrombotic risk"[Title/Abstract] OR "ischemic risk"[Title/Abstract] OR "ischaemic risk"[Title/Abstract] OR "Mortality"[Title/Abstract]

#4 - #1 AND #2 AND #3

Database: Web of Science

Last search date: 18 Dec 2023

Number of items: 1670

1 - TOPIC: (((("myocardial infarct*" OR (myocardial NEAR/0 infarction)) NEAR/2 "st segment*")))

Databases= WOS, DIIDW, KJD, MEDLINE, RSCI, SCIELO Timespan=All years

Search language=Auto

2 - TOPIC: (((("myocardial infarct*" OR (myocardial NEAR/0 infarction)) NEAR/2 eleva*))

Databases= WOS, DIIDW, KJD, MEDLINE, RSCI, SCIELO Timespan=All years

Search language=Auto

3 - TOPIC: (STEMI)

Databases= WOS, DIIDW, KJD, MEDLINE, RSCI, SCIELO Timespan=All years

Search language=Auto

4 - TOPIC: ("myocardial infarct*" OR (myocardial NEAR/0 infarction))

Databases= WOS, DIIDW, KJD, MEDLINE, RSCI, SCIELO Timespan=All years

Search language=Auto

5 - TOPIC: ("acute coronar* syndrom*" OR (acute NEAR/1 coronary NEAR/0 syndrome))

Databases= WOS, DIIDW, KJD, MEDLINE, RSCI, SCIELO Timespan=All years

Search language=Auto

6 - TOPIC: ("coronar* arter* diseas*" OR (coronary NEAR/0 artery NEAR/0 disease))

Databases= WOS, DIIDW, KJD, MEDLINE, RSCI, SCIELO Timespan=All years

Search language=Auto

7 - TOPIC: ("isch\$emic* heart diseas*" OR (ischemic NEAR/0 heart NEAR/0 disease))

Databases= WOS, DIIDW, KJD, MEDLINE, RSCI, SCIELO Timespan=All years

Search language=Auto

8 - TOPIC: ("percutan* coronar* intervention*" OR (percutaneous NEAR/0 coronary NEAR/0 intervention))

Databases= WOS, DIIDW, KJD, MEDLINE, RSCI, SCIELO Timespan=All years

Search language=Auto

9 - TOPIC: ((Drug-Eluting NEAR/0 Stent) OR "drug-elut* stent*") OR TOPIC: ((*metal* NEAR/0 stent*) OR "bare-metal stent*")

Databases= WOS, DIIDW, KJD, MEDLINE, RSCI, SCIELO Timespan=All years

Search language=Auto

10 - TOPIC: ((angioplast* NEAR/3 coronar*) OR (coronary NEAR/3 angioplasty))

Databases= WOS, DIIDW, KJD, MEDLINE, RSCI, SCIELO Timespan=All years

Search language=Auto

11 - TOPIC: ((stent* NEAR/3 coronar*) OR (coronary NEAR/3 stenting))

Databases= WOS, DIIDW, KJD, MEDLINE, RSCI, SCIELO Timespan=All years

Search language=Auto

12 - TOPIC: ("unstable angina" OR (unstable NEAR/0 angina))

Databases= WOS, DIIDW, KJD, MEDLINE, RSCI, SCIELO Timespan=All years

Search language=Auto

13 - #12 OR #11 OR #10 OR #9 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1

Databases= WOS, DIIDW, KJD, MEDLINE, RSCI, SCIELO Timespan=All years

Search language=Auto

14 - TOPIC: (((platelet* OR thrombocyt*) OR (platelet OR thrombocyte)) NEAR/2 ((volume OR size OR count* OR number* OR indic* OR parameter* OR index* OR marker*) OR (volume OR size OR count OR number OR indice OR parameter OR index OR marker)))

Databases= WOS, DIIDW, KJD, MEDLINE, RSCI, SCIELO Timespan=All years

Search language=Auto

15 - TOPIC: (((h\$ematol* OR h\$emogram*) OR (hematology OR hemogram OR hematological)) NEAR/2 ((indic* OR parameter* OR index* OR marker*) OR (indice OR parameter OR index OR marker)))
Databases= WOS, DIIDW, KJD, MEDLINE, RSCI, SCIELO Timespan=All years
Search language=Auto

16 - TOPIC: ((blood NEAR/2 platelet) OR (blood NEAR/2 platelet*))
Databases= WOS, DIIDW, KJD, MEDLINE, RSCI, SCIELO Timespan=All years
Search language=Auto

17 - TOPIC: ("mean platelet volume" OR (mean NEAR/0 platelet NEAR/0 volume))
Databases= WOS, DIIDW, KJD, MEDLINE, RSCI, SCIELO Timespan=All years
Search language=Auto

18 - TOPIC: ((large NEAR/1 platelet) OR (larg* NEAR/1 platelet*))
Databases= WOS, DIIDW, KJD, MEDLINE, RSCI, SCIELO Timespan=All years
Search language=Auto

19 - TOPIC: ((complet* blood count*) OR (complete NEAR/1 blood NEAR/1 count))
Databases= WOS, DIIDW, KJD, MEDLINE, RSCI, SCIELO Timespan=All years
Search language=Auto

20 - TOPIC: (thrombocytop* OR thrombocytopenia OR thrombocytosis)
Databases= WOS, DIIDW, KJD, MEDLINE, RSCI, SCIELO Timespan=All years
Search language=Auto

21 - #20 OR #19 OR #18 OR #17 OR #16 OR #15 OR #14
Databases= WOS, DIIDW, KJD, MEDLINE, RSCI, SCIELO Timespan=All years
Search language=Auto

22 - TOPIC: ((long-term OR short-term) NEAR/1 ((prognos* OR outcom* OR surviv*) OR (prognosis OR outcome OR survival)))
Databases= WOS, DIIDW, KJD, MEDLINE, RSCI, SCIELO Timespan=All years
Search language=Auto

23 - TOPIC: ((cardiovascular OR cardio-vascular OR cardiac OR cerebral OR cerebrovascular OR cerebro-vascular OR atherothromb* OR atherothrombotic OR athero-thromb* OR thromb* OR thrombotic OR isch\$emic OR ischemic) NEAR/1 (outcom* OR outcome OR endpoint* OR endpoint OR end-pont* OR end-pont OR complicat* OR complication))
Databases= WOS, DIIDW, KJD, MEDLINE, RSCI, SCIELO Timespan=All years
Search language=Auto

24 - TOPIC: (adverse NEAR/1 (cardi* OR cardiac OR cardiovascular OR cardio-vascular) NEAR/1 (cerebr* OR cerebral OR cerebrovascular OR cerebro-vascular) NEAR/1 (event* OR event OR outcome OR outcom* OR endpoint* OR endpoint OR end-pont* OR end-point))
Databases= WOS, DIIDW, KJD, MEDLINE, RSCI, SCIELO Timespan=All years
Search language=Auto

25 - TOPIC: (adverse NEAR/1 (cardi* OR cardiac OR cardiovascular OR cardio-vascular) NEAR/1 (event* OR event OR outcome OR outcom* OR endpoint* OR endpoint OR end-pont* OR end-point))

Databases= WOS, DIIDW, KJD, MEDLINE, RSCI, SCIELO Timespan=All years
Search language=Auto

26 - TOPIC: (MACCE)

Databases= WOS, DIIDW, KJD, MEDLINE, RSCI, SCIELO Timespan=All years
Search language=Auto

27 - TOPIC: ((cardiovascular OR cardio-vascular OR cardiac OR cerebral OR cerebrovascular OR cerebro-vascular OR atherothromb* OR atherothrombotic OR athero-thromb* OR thromb* OR thrombotic OR isch\$emic OR ischemic) NEAR/2 risk)

Databases= WOS, DIIDW, KJD, MEDLINE, RSCI, SCIELO Timespan=All years
Search language=Auto

28 - TOPIC: (mortality)

Databases= WOS, DIIDW, KJD, MEDLINE, RSCI, SCIELO Timespan=All years
Search language=Auto

29 - TOPIC: ((cardiovascular OR cardio-vascular OR cardiac OR cerebral OR cerebrovascular OR cerebro-vascular OR atherothromb* OR atherothrombotic OR athero-thromb* OR thromb* OR thrombotic OR isch\$emic OR ischemic) NEAR/2 death)

Databases= WOS, DIIDW, KJD, MEDLINE, RSCI, SCIELO Timespan=All years
Search language=Auto

30 - TOPIC: ((proport* OR proportional) NEAR/1 (hazard* OR hazard) NEAR/1 (model* OR model OR analys\$ OR analysis))

Databases= WOS, DIIDW, KJD, MEDLINE, RSCI, SCIELO Timespan=All years
Search language=Auto

31 - TOPIC: (reinfarction OR re-infarction)

Databases= WOS, DIIDW, KJD, MEDLINE, RSCI, SCIELO Timespan=All years
Search language=Auto

32 - TOPIC: ((coronar* OR coronary) NEAR/1 (restenos* OR re-stenos* OR restenosis OR re-stenosis))

Databases= WOS, DIIDW, KJD, MEDLINE, RSCI, SCIELO Timespan=All years
Search language=Auto

33 - TOPIC: ((stent* OR stent) NEAR/0 (thromb* OR thrombosis))

Databases= WOS, DIIDW, KJD, MEDLINE, RSCI, SCIELO Timespan=All years
Search language=Auto

34 - TOPIC: (kaplan-meir NEAR/2 (curve* OR analys\$ OR curve OR analysis))

Databases= WOS, DIIDW, KJD, MEDLINE, RSCI, SCIELO Timespan=All years
Search language=Auto

35 - TOPIC: ((surviv* OR survival) NEAR/0 (analys\$ OR rate* OR analysis OR rate))

Databases= WOS, DIIDW, KJD, MEDLINE, RSCI, SCIELO Timespan=All years
Search language=Auto

36 - TOPIC: ("roc curve*" OR (roc near/0 curve))

Databases= WOS, DIIDW, KJD, MEDLINE, RSCI, SCIELO Timespan=All years
Search language=Auto

37 - TOPIC: ("area under curve*" OR (area NEAR/0 under NEAR/0 curve))
Databases= WOS, DIIDW, KJD, MEDLINE, RSCI, SCIELO Timespan=All years
Search language=Auto

38 - TOPIC: ((revasculari\$ation OR re-vasculari\$ation OR revascularization OR
re-vascularization) NEAR (("target vessel*" OR "target lesion*") OR (target NEAR (vessel OR
lesion))))
Databases= WOS, DIIDW, KJD, MEDLINE, RSCI, SCIELO Timespan=All years
Search language=Auto

39 - #38 OR #37 OR #36 OR #35 OR #34 OR #33 OR #32 OR #31 OR #30 OR #29
OR #28 OR #27 OR #26 OR #25 OR #24 OR #23 OR #22
Databases= WOS, DIIDW, KJD, MEDLINE, RSCI, SCIELO Timespan=All years
Search language=Auto

40 - #39 AND #21 AND #13
Databases= WOS, DIIDW, KJD, MEDLINE, RSCI, SCIELO Timespan=All years
Search language=Auto

Database: Scopus

Last search date: 18 Dec 2023

Number of items: 3357

#1 – Patient: ((TITLE-ABS-KEY ("myocardial infarction" W/2 "st segment")) OR (TITLE-ABS-KEY ("myocardial infarction" W/2 eleva*)) OR (TITLE-ABS-KEY (stemi)) OR (TITLE-ABS-KEY ("myocardial infarction")) OR (TITLE-ABS-KEY ("acute coronary syndrome")) OR (TITLE-ABS-KEY ("coronary artery disease")) OR (TITLE-ABS-KEY ("ischemic heart disease")) OR (TITLE-ABS-KEY ("ischaemic heart disease")) OR (TITLE-ABS-KEY ("Percutaneous Coronary Intervention")) OR (TITLE-ABS-KEY ("Drug-Eluting Stents")) OR (TITLE-ABS-KEY ("metal stent")) OR (TITLE-ABS-KEY (angioplasty W/3 coronary)) OR (TITLE-ABS-KEY (stent W/3 coronary)) OR (TITLE-ABS-KEY ("unstable angina")))

#2 – Exposure: ((TITLE-ABS-KEY ((platelet OR thrombocyte) W/2 (volume OR size OR count OR number OR indice OR parameter OR index OR marker))) OR (TITLE-ABS-KEY ("mean platelet volume")) OR (TITLE-ABS-KEY ("blood platelet")) OR (TITLE-ABS-KEY ((hematological OR hemogram OR hematologic OR haematological OR haemogram) W/1 (indice OR parameter OR index OR marker))) OR (TITLE-ABS-KEY ("large platelet")) OR (TITLE-ABS-KEY ("complete blood count")) OR (TITLE-ABS-KEY (complete W/1 blood W/1 count)) OR (TITLE-ABS-KEY (thrombocytopenia OR thrombocytosis OR thrombocytop*)))

#3 – Outcome: ((TITLE-ABS-KEY ((long-term OR short-term) PRE/1 (prognosis OR outcome OR survival))) OR (TITLE-ABS-KEY ((cardiovascular OR cardio-vascular OR cardiac OR cerebral OR cerebrovascular OR cerebro-vascular OR atherothrombotic OR athero-thrombotic OR atherothromb* OR athero-thromb* OR thrombotic OR thrombo* OR ischemic OR ischaemic) PRE/1 (outcome OR endpoint OR complication OR end-point OR "end point")))) OR (TITLE-ABS-KEY (adverse PRE/1 (cardiac OR cardiovascular OR cardio-vascular) PRE/1 (cerebral OR cerebrovascular OR cerebro-vascular) PRE/1 (event OR outcome OR endpoint OR end-point OR "end point")))) OR (TITLE-ABS-KEY (adverse PRE/1 (cardiac OR cardiovascular OR cardio-vascular) PRE/1 (event OR outcome OR endpoint OR end-point)))) OR (TITLE-ABS-KEY (MACCE)) OR (TITLE-ABS-KEY ((cardiovascular OR cardio-vascular OR

cardiac OR cerebral OR cerebrovascular OR cerebro-vascular OR atherothrombotic OR athero-thrombotic OR atherothromb* OR athero-thromb* OR thrombotic OR thrombo* OR ischemic OR ischaemic) W/2 risk)) OR (TITLE-ABS-KEY (mortality)) OR (TITLE-ABS-KEY ((cardiovascular OR cardio-vascular OR cardiac OR cerebral OR cerebrovascular OR cerebro-vascular OR atherothrombotic OR athero-thrombotic OR atherothromb* OR athero-thromb* OR thrombotic OR thrombo* OR ischemic OR ischaemic) W/2 death)) OR (TITLE-ABS-KEY (proportional PRE/1 hazard PRE/1 (model OR analysis))) OR (TITLE-ABS-KEY (reinfarction)) OR (TITLE-ABS-KEY ("coronary restenosis")) OR (TITLE-ABS-KEY (coronary W/1 restenosis)) OR (TITLE-ABS-KEY (coronary W/1 re-stenosis)) OR (TITLE-ABS-KEY ("stent thrombosis")) OR (TITLE-ABS-KEY (stent W/1 thrombosis)) OR (TITLE-ABS-KEY ("kaplan-meir" PRE/2 (curve OR analysis))) OR (TITLE-ABS-KEY (survival PRE/0 (analysis OR rate))) OR (TITLE-ABS-KEY ("roc curve")) OR (TITLE-ABS-KEY ("area under curve")) OR (TITLE-ABS-KEY (revascularization w/2 ("target vessel" OR "target lesion"))))

#4 - #1 AND #2 AND #3

Supplementary Tables.

Supplementary Table 1. Additional sources.

Name	Last search date	Search strategy	Number of results
Registries			
ClinicalTrials.gov https://clinicaltrials.gov/	Mar/5/2024	("Mean Platelet Volume" OR "Platelet Size" OR "Large Platelet" OR "Platelet Volume") AND ("Acute Coronary Syndrome" OR "Myocardial Infarction" OR "Unstable angina" OR "Coronary Artery disease")	25
The Australian New Zealand Clinical Trials Registry https://www.anzctr.org.au/	Mar/5/2024	platelet AND "Coronary Artery disease"	183
Chinese Clinical Trial Registry http://www.chictr.org.cn/abouten.aspx	Mar/5/2024	"Platelet"; Filter: cohort studies	362
The European Union Clinical Trials Register	Mar/9/2024	platelet AND "coronary artery disease"	65

https://www.clinicaltrialsregister.eu/			
German Clinical Trial Registry https://www.drks.de/	Mar/9/2024	Platelet AND "coronary artery disease"	24
Japan Primary Registries Network https://rctportal.niph.go.jp/	Mar/5/2024	myocardial infarction AND platelet	1
Clinical Research Information Service, Republic of Korea https://cris.nih.go.kr/cris/	Mar/5/2024	Platelet; Filter: disease of the circulatory system	5
Iranian Registry of Clinical Trials https://www.irct.ir/	Mar/9/2024	Platelet AND "coronary artery disease"	14
Peruvian Clinical Trial Registry https://ensayosclinicos-repec.ins.gob.pe/en/	Mar/5/2024	Filter: cardiology “myocardial infarction” “acute coronary syndrome”	1
Brazilian Registry of Clinical Trials http://www.ensaiosclinicos.gov.br/	Mar/9/2024	platelet AND coronary artery disease	10
Clinical Trials Registry-India https://ctril.icmr.org.in/	Mar/9/2024	coronary artery disease	426
International Standard Randomised Controlled Trial Number registry https://www.isRCTN.com/	Mar/5/2024	Platelet Filter: Circulatory System	142
Journal websites			
Taylor and Francis journals https://www.tandfonline.com/	Mar/9/2024	"mean platelet volume" AND "coronary artery disease"	374

Nature journals https://www.nature.com/	Mar/9/2024	"mean platelet volume" AND "coronary artery disease"	97
PLOS ONE journal https://journals.plos.org/plosone/	Mar/9/2024	"mean platelet volume" AND "coronary artery disease"	74
SAGE publisher https://journals.sagepub.com/	Mar/9/2024	"mean platelet volume" AND "coronary artery disease"	337
The American Journal of Cardiology https://www.ajconline.org/	Mar/9/2024	"mean platelet volume" Filters: Research Article	1195
Atherosclerosis https://www.atherosclerosis-journal.com/	Mar/9/2024	"mean platelet volume" Filters: Research Article	1017
The International Journal of Cardiology https://www.internationaljournalofcardiology.com/	Mar/9/2024	"mean platelet volume" Filters: Research Article	635
Blood Coagulation and Fibrinolysis https://journals.lww.com/bloodcoagulation/	Mar/9/2024	"mean platelet volume" AND "coronary artery disease" Filters: Articles	57
Journals of American College of Cardiology https://www.jacc.org	Mar/9/2024	"mean platelet volume" Filters: Original Research	2329
Springer journals https://link.springer.com/	Mar/9/2024	"mean platelet volume" AND "coronary artery disease" Filters: Article, Medicine and Public Health, Cardiology	137
Thrombosis Research https://www.thrombosisresearch.com	Mar/9/2024	"mean platelet volume" Filters: Research Article	3056

Other sources			
Biomed Explorer https://sites.research.google/biomedexplorer/	Mar/9/2024	“What is the prognostic role of mean platelet volume in coronary artery disease?”	100
Conferences from the European Society of Cardiology https://esc365.escardio.org/	Mar/5/2024	"mean platelet volume" Filters: Topic — coronary artery disease, acute coronary syndromes, acute cardiac care, interventional cardiology and cardiovascular surgery, preventive cardiology	3393
TCT portal https://www.tctmd.com/see-all/conference	Mar/5/2024	"mean platelet volume" Filter: all conferences	1
CoCites tool https://www.cocites.com/	Mar/9/2024	CoCites plugin for web browsers were used for PubMed search.	1520

Supplementary Table 2. A list of some excluded studies with reasons for exclusion.

First author, year	Citation	Reasons for exclusion
Adam, 2018	Adam AM, Rizvi AH, Haq A, Naseem R, Rehan A, Shaikh AT, Abbas AH, Godil A, Ali A, Mallick MSA, Khan MS, Lashari MN. Prognostic value of blood count parameters in patients with acute coronary syndrome. Indian Heart J. 2018 Mar-Apr;70(2):233-240. doi: 10.1016/j.ihj.2017.06.017. Epub 2017 Jun 30. PMID: 29716700; PMCID: PMC5993917.	It is a second publication related to the study cohort already included in the meta-analysis
Ayça B, 2015	Ayça B, Akin F, Çelik Ö, Yüksel Y, Öztürk D, Tekiner F, Çetin Ş, Okuyan E, Dinçkal M H. Platelet to lymphocyte ratio as a prognostic marker in primary percutaneous coronary intervention. Platelets. 2015;26(7):638-44. doi: 10.3109/09537104.2014.968117. Epub 2014 Oct 28. PMID: 25350375.	The study provided an odds ratio for inhospital MACE with MPV treated as a continuous variable. There were only 2 studies for this analysis, therefore we excluded these studies

Celik T, 2013	Celik T, Kaya MG, Akpek M, Gunebakmaz O, Balta S, Sarli B, Duran M, Demirkol S, Uysal OK, Oguzhan A, Gibson CM. Predictive value of admission platelet volume indices for in-hospital major adverse cardiovascular events in acute ST-segment elevation myocardial infarction. <i>Angiology.</i> 2015 Feb;66(2):155-62. doi: 10.1177/0003319713513493. Epub 2013 Dec 3. PMID: 24301422.	The study provided an odds ratio for inhospital MACE with MPV treated as a continuous variable. There were only 2 studies for this analysis, therefore we excluded these studies
Ceylan, 2023	Ceylan US, Yaman AE. Evaluation of the inflammatory parameters for predicting stent thrombosis. <i>Bratisl Lek Listy.</i> 2023;124(6):475-479. doi: 10.4149/BLL_2023_073. PMID: 36876384.	Wrong study design
Ebina T, 2021	Ebina T, Tochihara S, Okazaki M, Koike K, Tsuto Y, Tayama M, Takanami Y, Hirose H, Horii M, Okada K, Matsuzawa Y, Maejima N, Iwahashi N, Hibi K, Kosuge M, Tamura K, Kimura K. Impact of red blood cell distribution width and mean platelet volume in patients with ST-segment elevation myocardial infarction. <i>Heart Vessels.</i> 2022 Mar;37(3):392-399. doi: 10.1007/s00380-021-01936-6. Epub 2021 Sep 13. PMID: 34518907.	The adjusted statistics for MPV were not provided
Ki, 2013	Ki YJ, Park S, Ha SI, Choi DH, Song H. Usefulness of mean platelet volume as a biomarker for long-term clinical outcomes after percutaneous coronary intervention in Korean cohort: a comparable and additive predictive value to high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide. <i>Platelets.</i> 2014;25(6):427-32. doi: 10.3109/09537104.2013.835393. Epub 2013 Oct 8. PMID: 24102424.	It is a publication related to a cohort of patients already included in the meta-analysis
Małyszczak, 2020	Małyszczak A, Łukawska A, Dyląg I, Lis W, Mysiak A, Kuliczkowski W. Blood Platelet Count at Hospital Admission Impacts Long-Term Mortality in Patients with Acute Coronary Syndrome. <i>Cardiology.</i> 2020;145(3):148-154. doi: 10.1159/000505640. Epub 2020 Feb 4. PMID: 32018251.	The adjusted statistics for MPV were not provided

Moon, 2016	Moon AR, Choi DH, Jahng SY, Kim BB, Seo HJ, Kim SH, Ryu SW, Song H, Kim TH. High-sensitivity C-reactive protein and mean platelet volume as predictive values after percutaneous coronary intervention for long-term clinical outcomes: a comparable and additive study. <i>Blood Coagul Fibrinolysis.</i> 2016 Jan;27(1):70-6. doi: 10.1097/MBC.0000000000000398. PMID: 26340462.	It is a publication related to a cohort of patients already included in the meta-analysis
Ndrepepa G, 2022	Ndrepepa G, Holdenrieder S, Kastrati A. Prognostic value of De Ritis ratio in patients with acute myocardial infarction. <i>Clin Chim Acta.</i> 2022 Oct 1;535:75-81. doi: 10.1016/j.cca.2022.08.016. Epub 2022 Aug 17. PMID: 35985502.	The adjusted statistics for MPV were not provided
Odeberg J, 2016	Odeberg J, Freitag M, Forssell H, Vaara I, Persson ML, Odeberg H, Halling A, Råstam L, Lindblad U. Influence of pre-existing inflammation on the outcome of acute coronary syndrome: a cross-sectional study. <i>BMJ Open.</i> 2016 Jan 12;6(1):e009968. doi: 10.1136/bmjopen-2015-009968. PMID: 26758266; PMCID: PMC4716249.	Wrong study design
Sun XP, 2016	Sun XP, Li J, Zhu WW, Li DB, Chen H, Li HW, Chen WM, Hua Q. Impact of Platelet-to-Lymphocyte Ratio on Clinical Outcomes in Patients With ST-Segment Elevation Myocardial Infarction. <i>Angiology.</i> 2017 Apr;68(4):346-353. doi: 10.1177/0003319716657258. Epub 2016 Jul 11. PMID: 27381032.	The study provided an odds ratio for long-term MACE with MPV treated as a continuous variable. There were only 2 studies for this analysis, therefore we excluded these studies
Turen S, 2023	Turen S, Memic Sancar K. Predictive Value of the Prognostic Nutritional Index for Long-Term Mortality in Patients with Advanced Heart Failure. <i>Acta Cardiol Sin.</i> 2023 Jul;39(4):599-609. doi: 10.6515/ACS.202307_39(4).20221223A. PMID: 37456943; PMCID: PMC10346059.	Wrong population
Yang L, 2018	Yang L, Wang H, Zhang Y, Han T, Wang W. The Prognostic Value of Lipoprotein-Associated	The study provided an odds ratio for long-term MACE with

	Phospholipase A2 in the Long-Term Care of Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. Clin Appl Thromb Hemost. 2018 Jul;24(5):822-827. doi: 10.1177/1076029617737837. Epub 2017 Nov 9. PMID: 29121808; PMCID: PMC6714881.	MPV treated as a continuous variable. There were only 2 studies for this analysis, therefore we excluded these studies
Zhao Y, 2022	Zhao Y, Zhou P, Gao W, Zhong H, Chen Y, Chen W, Waresi M, Xie K, Shi H, Gong H, He G, Qiu Z, Luo X, Li J. Cilostazol combined with P2Y12 receptor inhibitors: A substitute antiplatelet regimen for aspirin-intolerant patients undergoing percutaneous coronary stent implantation. Clin Cardiol. 2022 Feb;45(2):189-197. doi: 10.1002/clc.23787. Epub 2022 Feb 4. PMID: 35120275; PMCID: PMC8860475.	The adjusted statistics for MPV were not provided

Supplementary Table 3. Baseline features of the included studies

Study, year	Osunna, 1998	Huczek, 2005	Estevez-Loureiro, 2009	Vakili, 2009	Akpek, 2011	Goncalves, 2011	Taglieri, 2011	Tekbas, 2011	Dogan, 2012	Lopez-Cuenca, 2012	Vrsalovic, 2012	Eisen, 2013	Akgul, 2013	Fabregat-Andreas, 2013	Nozari, 2013	Unal, 2013
Country	Spain	Poland	Spain	Iran	Turkey	Australia	Italy	Turkey	Turkey	Spain	Croatia	Israel	Turkey	Spain	Iran	Turkey
Study design	-	Prospective cohort	Prospective cohort	Retrospective cohort	Prospective cohort	Prospective cohort	Retrospective cohort	Retrospective cohort	Prospective cohort	Prospective cohort	Prospective cohort	Retrospective cohort	Prospective cohort	Retrospective cohort	Retrospective cohort	Prospective cohort
Follow-up, months	in hospital	6	1	inhospital	inhospital	12	12	24.2	12	6	1	48	6	12	12	2
Sample size, n	1082	388	617	203	289	1102	1041	429	344	329	543	4961	495	128	2539	205
Diagnosis	STEMI, 100%	STEMI, 100%	STEMI, 100%	STEMI, 100%	STEMI, 100%	ACS, 100%	NST-A CS, 100%	STEMI 65%; NSTE MI 35%	NSTE MI 37%, UA 63%	NSTE ACS, 100%	STE MI, 100%	ACS, 100%	STE MI, 100%	STEMI, 100%	Stable CAD patients treated with PCI	Stable CAD patients

Mean age, years	68±13	60±1.3	63±12	56±11.2	58±12	62.8±11.5	76 (67-82)	61.9±2.4	61.9±7.7	67.3±12.3	67.8	67.1±2.5	55.6±12.4	59.5±14.1	58±10.6	60.9±10.3
Males, %	78	72.2	81	78.8	80	72.8	74.2	70.4	69.6	64	63.4	75.5	80.2	80.2	69.8	82
Hypertension, %	43.5	62.6	37.5	31.5	44.7	60.2	79.7	43.4	49.1	69.4	58.4	70.5	34.3	59.2	50.1	62.9
Diabetes mellitus, %	19.8	16.5	17.5	22.7	28.3	27.9	25.4	52.2	34.1	40.6	27.4	38.7	20.2	37.9	27.5	35.6
Dyslipidemia, %	18.9	42	33.5	36.9	-	71.5	56.7	18.9	44.1	55.7	31.1	-	-	53	67.4	54.6
Smoking, %	55.2	55.2	35	47.8	60.6	15.9	43.5	43.4	44.9	58	52.3	40.5	-	55.5	28.3	-
Previous MI, %	36.3	20.1	-	12.3	-	24.7	38.5	10.5	-	17.2	-	-	16.6	-	49.6	-
Family history of CAD, %	-	-	6.5	-	-	-	16.3	20.7	21.1	-	-	-	-	-	20	-

History of PCI, %	-	-	-	-	-	-	23.5	-	-	17	-	-	-	-	0	-
BMI, kg/m ²	-	-	-	-	26.1±2.6	-	-	-	-	27.8	-	-	-	-	-	-
Baseline SBP, mmHg	-	129.3±19.8	-	119.7±27	-	-	140 (125-160)	124.9±21.6	-	-	-	-	134.8±58.5	-	-	-
Glucose, mg/dl	-	-	-	-	176.5±97.1	-	-	147.7±77.7	-	-	-	-	168.9±83.3	112.5±36	-	-
Cholesterol, mg/dl	-	-	190.8±46	-	179.5±43	-	-	-	-	-	-	-	196.4±46.8	166.2±50	-	-
LDL-C, mg/dl	-	-	119.8±39.1	-	117.9±32.8	-	-	-	-	-	-	-	131.6±36.7	113.9±36	-	-
HDL-C, mg/dl	-	-	47.7±12.7	-	39.0±113.3	-	-	-	-	-	-	-	40.9±10.3	37.2±	-	-
Fasting triglycerides, mg/dl	-	-	-	-	115.1±60.8	-	-	-	-	-	-	-	128.3±89	-	-	-
Creatinine, mg/dl	-	-	0.98	-	-	1.14±0.73	1.2 (1.02-1.52)	1.16±0.4	1.1	0.95 (0.80-1.13)	1.25	1.05±0.7	0.9±0.4	0.9±0.2	1.06±0.4	0.93 [0.80-1.07]

WBC, 10 ⁹ /l	-	-	11.0	-	12.3± 4.7	-	8.6 (6.9-10 .9)	11.8±4 .2	8.0	8.1 (6.7-9 .9)	10.5	-	12.3± 4.2	-	-	8.27± 1.93			
Hemoglobin, g/l	-	-	-	-	144.1 ±17.6	138.2 ±16.3	134 (120-1 48)	13.3±1 .8	134.3 ±1.3	138± 18	-	135±1 7	-	137±1 6	139.8± 1.7	14.4± 1.6			
Platelet count, 10 ⁹ /l	-	-	257.5 ±101. 1	-	243.7 ±65.8	247± 74.1	241 (199-2 99)	277.7± 85.3	265	209 (174- 252)	246.5	243.7± 71.1	257± 71.4	233±6 2	226.3± 63.3	268±6 7			
MPV, fl	8.8± 1.03	10.0± 0.9	8.8	9.55±0 .88	10.4± 0.9	8.7±1 .3	-	10.4±2		11 (10.3- 11.8)	-	8.55±1 .1	8.4±1 .1	9.1±1. 1	-	-			
EF, %	-	-	57±14	-	48.4± 10.6	-	-	50.3±9 .4	53.4	-	53.7	-	-	52.1±1 0.8	-	55.0 [50-6 0]			
PCI, %	-	100	100	100	100	-	68.4	-	61.3	-	100	100	100	100	100	100	-		
Anterior MI, %	-	43.8	41	65.1	-	-	-	-	-	-	40.7	-	44.4	40.3	-	-	-		
MVD, %	-	22.7	48	-	51.9	-	56.1	-	45.6	-	51.8	77	-	-	-	-	-		
GPI use, %	-	52.1	61	10.9	15.6	-	-	-	-	-	-	-	33.3	-	-	-	-		

(Continued) Supplementary Table 3. Baseline features of the included studies.

Study, year	Bergoli, 2014	Lekston, 2014	Choi, 2014	Liu, 2014	Seo, 2014	Seyyed-Mohammadza, 2014	Siller-Matula, 2014	Wan, 2014	Ghaffari, 2015	Lai, 2015	Navarata, 2015	Ranjith, 2015	Lai, 2016	Wasilewski, 2016	Tongting Yu, 2017	Gina Yu, 2017
Country	Brazil	Poland	Korea	China	South Korea	Iran	Austria	China	Iran	China	Argentina	India	China	Poland	China	China
Study design	Prospective cohort	Retrospective cohort	Retrospective cohort	Prospective cohort	Retrospective cohort	Prospective cohort	Prospective cohort	Prospective cohort	Prospective cohort	Prospective cohort	Prospective cohort	Prospective cohort	Prospective cohort	Retrospective cohort	Retrospective cohort	Retrospective cohort
Follow-up, months	1	12	12	inhospital	25.8	12	24	52	6	1	10.1	12	1	12	28	1
Sample size, n	168	1557	122	190	372	181	404	286	191	649	250	1206	453	1001	887	608
Diagnosis	STEMI, 100%	STEMI, 100%	ACS, 100%	NSTE MI, 100%	All CAD patients treated	Stable CAD patients treated	All CAD patients treated	ACS	STE MI, 100%	STE MI, 100%	STE MI, 22%; NSTE	STEMI, 66.09%; NSTE	STE MI, 100%	NSTE MI, 100%	NSTE MI, 100%	STE MI, 100%

					d with PCI	d with PCI	with PCI				MI, 26.8 %; UA 51.2	MI, 33.91 %				
Mean age, years	60.7±1 2.7	61.9±9 .9	65.4± 11.6	66.8±1 2.7	65.2± 10.7	58.2± 10.9	64.4±1 2	59.4±1 2	60±1 1	59.1± 11.8	74±7	56±11	56.2± 8.4	64.7 ± 10.7	62.5±1 1.6	62.7± 13.1
Males, %	66.3	67.6	66.8	65.8	63.2	68.5	51.5	61.2	82.2	82.3	56.4	77.4	84.5	66.6	67.3	79.1
Hyperte nsion, %	61.3	63.8	54.8	70	57.3	49.2	84.4	41.9	37.7	45.8	81.6	34.7	41.5	65.3	60.6	49.7
Diabete s mellitus , %	15.6	34.6	32.7	32.1	33.3	16.6	31.9	21.3	22	32.5	26	30.0	25.2	30.3	35.8	-
Dyslipi demia, %	-	-	7.7	17.4	25.8	48.1	76.2	-	16.2	74	58.8	23.6	-	31.2	71	13
Smokin g, %	68.4	-	49	36.9	48.4	44.8	55.2	46.8	40.8	30.7	26	41.3	29.8	21.1	48.8	-
Previo us MI, %	7.1	28.3	-	12.1	-	39.2	32.2	-	0	-	20.8	-	-	34.7	9.1	-

Family history of CAD, %	-	-	1.4	-	2.2	29.8	-	-	7.9	-	-	-	15.5	24.6	-	-
History of PCI, %	9.6	-	-	11.6	-	18.2	-	-	-	18.4	-	4.2	26.8	11	11.5	
BMI, kg/m ²	-	26±1.9	-	-	24.2±3.4	27.4±4.4	28±5	-	-	25.8±3.6	-	-	26±3.5	28.6±4.8	-	-
Baseline SBP, mmHg	-	-	-	-	133.9±22.2	-	-	120.4±17.6	-	121.3±20.4	146±29	-	121.1±19.7	150.8±28.7	137.3±23.4	127±3.8
Glucose, mg/dl	-	156.8±71	-	-	119.8±37.6	-	-	102.7±39.6	171±91	113.5±42.3	-	-	100.9±31.5	116.4	-	-
Cholesterol, mg/dl	-	231.7	-	-	151.8±36.7	157.5±34.2	-	150.2±27.6	-	183.4±37.1	-	185.5±45.4	184.6±32.8	-	-	-
LDL-C, mg/dl	-	146.7	-	-	88.8±30	86.7±25	-	107.48	-	101.2±33.2	-	119.7±54.3	102.3±18.2	-	-	-
HDL-C, mg/dl	-	54.1	-	-	44.3±11	40.6±9.1	-	33.6±8	-	43.2±22.4	-	-	41.3±8.9	-	-	-
Fasting triglyc	-	123.9	-	-	135.8±78.1	172.6±87.7	-	131.9±71.3	-	144.3±80.5	-	116.0±44.8	150.4±64.6	-	-	115.9±132.3

rides, mg/dl																	
Creatinine, mg/dl	1.0±0.8	1.24	1.2±1.0	-	1.17±0.58	0.9±0.5	-	-	1.2±1.2	-	1.0±0.5	1.1±0.4	1±0.2	1.05	1.04±0.4	1.2±1.0	
WBC, 10 ⁹ /l	-	11.9±5	-	-	-	-	-	-	12.3±2.1	9.7±2.8	8.85±3.8	-	10.3±3.7	9.2	7.6±2.4	11.6±4	
Hemoglobin, g/l	-	144.6±13.9	133±2	-	-	-	141.7±9	-	-	138±13.6	-	-	138.2±13.4	136.6±17.5	133±17.7	143.6±2	
Platelet count, 10 ⁹ /l	-	207±6.9	252±7.2	194.8±56.3	-	209±56.9	227.6±72	-	242.7±56.8	211.7±52.1	210±75	238.5±65.7	220.8±65.5	-	202.3±56.3	246±7.7	
MPV, fl	-	9.7	8.61±0.9	9.5±1.6	-	-	-	11.5±1.1	8.2±1.8	10.5±1.2	10.6±0.6	9.2±1.0	9.8±0.9	11±1.1	9.4±1.5	-	
EF, %	-	44.6	58.8±11.2	58.6±7.6	59.8±11.8	-	-	59.7±1.3	-	50.8±5.4	-	57.5±1.0.5	49.6±6	43.9±1.0	57.1±1.0	44.6±12.2	
PCI, %	100	-	100	-	100	100	100	-	48.7	100	47.2	-	100	100	100	-	
Anterior MI, %	47.3		-	23.7	-	-	-	-	71.7	52.7	-	-	47.2	-	-	-	
MVD, %	-	44.4	-	-	-	-	-	-	47.4	71.3	-	-	41.9	68.4	-	-	

GPI use, %	58	-	-	-	-	-	-	-	-	42.7	-	-	43.7	8.7	25.5	-
---------------	----	---	---	---	---	---	---	---	---	------	---	---	------	-----	------	---

(Continued) Supplementary Table 3. Baseline features of the included studies.

Study, year	Adam, 2018	Mach ado, 2018	Monte iro Júnior , 2018	Tian, 2018	Niu, 2018	Wada 2018	Cang a, 2019	Chan g, 2019	Garlob o, 2019	Navart a, 2019	Nozari , 2019	Satiro glu, 2019	Jiang, 2019	Vogia tzis, 2019	Xinsen , 2020
Country	Pakist an	Brazi l	Brazil	China	China	Japan	Turke y	Taiwa n	Cuba	Argent ina	Iran	Turke y	China	Greec e	China
Study design	Prospe ctive cohort	Prosp ective cohor t	Prosp ective cohort	Retro specti ve cohor t	Retros pectiv e cohort	Prosp ective cohor t	Retro specti ve cohor t	Prosp ective cohor t	-	Prospe ctiv e cohort	Retros pectiv e cohort	Retros pecti ve cohor t	Prosp ective cohor t	Retro specti ve cohor t	Retros pective cohort
Follow- up, months	1	in-ho spital	in-hos pital	30	12	67.2	1	28.8	in-hos pital	8.6	12	in-ho spital	24	in-ho spital	in-hosp ital
Sample size, n	250	625	466	1215	2693	2872	349	1094	188	195	4199	194	1389	104	516

Diagnosis	STEMI, 39.6%; NSTE MI, 26.4%; UA 34	STE MI, 100%	STE MI, 70; NSTE MI, 30%	STE MI, 100%	STEMI, 49.43; NST-A CS, 50.57 %	Stable CAD patients treated with PCI	STE MI, 100%	STE MI, 27.25 %; NST EMI, 44.52 %; UA, 28.23 %	Acute MI, 100%	STEMI, 100% %; NST-A CS, 79.49 %	NST-A CS, 100%	STE MI, 100%	Stable CAD patients treated with PCI	STE MI, 32.7 %; NST EMI, 29.8 %; UA, 37.5 %	STEMI , 100%
Mean age, years	55.1±1 0.7	60.7± 12.1	64.2± 12.8	61.5± 12.4	61.1± 1.8	67.0± 10.0	36.4± 3.6	69±1 3	-	74±7	59.9±1 0.3	78.5± 4.7	59±9. 5	64.2± 11.1	65.4±8. 6
Males, %	65.2	67.5	61.6	73.9	75.8	83.1	90	71.1	69.7	57	65.7	53	76.2	76	57.6
Hypertension, %	70.4	59	71.9	48.6	47.4	74.3	14	68.3	80.9	80	59.8	55.2	69	-	61.8
Diabetes mellitus, %	34	23.7	37.1	32.3	20.8	46.2	13.2	51.4	27.7	26.7	32.6	38.7	100	-	49.6
Dyslipidemia, %	-	-	38.2	66	70.8	74.9	12.3	53.4	4.2	56.9	68.7	44.8	74.7	-	19.4

Smoking, %	29.2	63.1	41.6	56.6	50.4	22.9	81.7	28.7	58.5	20.5	22.4	8.8	53.9	-	52.7
Previous MI, %	-	9.0	-	4.6	10.8	-	-	-	-	11.8	-	-	26.5	-	-
Family history of CAD, %	40	-	47.2	-	-	28.2	14	-	-	-	18.1	-	-	-	-
History of PCI, %	-	10.9	-	4	-	-	-	-	-	11.8	15	-	30.6	-	-
BMI, kg/m ²	-	27.32 ±8.68	-	-	24.1±2.8	24.3±3.4	-	25±4	-	-	28±4.5	-	26.3±3.2	-	-
Baseline SBP, mmHg	129.4±29.4	-	-	128±22	124.1±17.4	-	127.6±17.7	-	-	-	-	-	129.4±16.8	-	125.2±19.1
Glucose, mg/dl	-	-	-	-	113.8±39.2	108.4±33.2	128.8±60.4	-	-	129.6±36.6	103.0 (91.0, 132.0)	117.3±48.4	135.14±43.24	-	98.2±39.1
Cholesterol, mg/dl	-	-	-	-	-	-	184.4±51.8	-	-	-	173.9±47.1	176.5±41.4	152.51±38.61	-	162.21±44.08

LDL-C, mg/dl	-	-	-	-	97.7±3 3.7	103.5 ±30.5	114.9 ± 42.8	112± 41	-	-	102.0 (78.5, 131.0)	111± 35.6	87.64 ±30.1 2	-	96.53
HDL-C, mg/dl	-	-	-	-	-	43.9± 12.7	34.5 ± 8.5	-	-	-	40.9±1 0.8	39.2± 9.3	37.84 ±8.88	-	37.45
Fasting triglyce rides, mg/dl	-	-	-	-	-	134.9 ±81.4	141± 106.0	-	-	-	147.0 (106.5, 209.0)	111.2 ±50.6	139.8 2±65. 49	-	162.57 ±106.8 5
Creatini ne, mg/dl	-	-	-	0.96± 0.54	0.99±0 .2	-	0.83 ± 0.29	2.13± 2.5	-	1.06±0 .6	0.9 (0.8, 1.1)	0.9±0 .3	-	1.0±0 .3	0.83±0. 46
WBC, $10^9/l$	10.5±3 .2	-	10.5 (8.4, 12.8)	9.5±3 .2	7.7±2. 2	5.8±1 .9	12.0 ± 3.7	10.5± 4.8	-	8.3±3. 1	-	9.9±3 .7	6.72± 1.73	-	-
Hemogl obin, g/l	124.8± 1.6	-	130±2	135.2 ±17.8	147.8± 19.7	132± 18	-	128± 25	-	-	140± 17	131.5 ±16.9	142.7 ±15.6	-	-
Platelet count, $10^9/l$	259.7± 65.6	-	231 (195.7 , 278)	203.1 ±56.3	177.7± 60.2	204± 58	244.3 ±65.1	217± 75	-	207±4 5.7	-	241± 65	-	-	
MPV, fl	11.1±1 .4	10.7 (10– 11.3)	10.9± .6	9.5±1 .6	11.6±1 .3	-	8.0±1 .2	8.6±1 .1	-	10.5±0 .5	-	8.2±1 .3	-	10.7± 1.2	10.7±0. 91
EF, %	46±11. 2	-	-	54.9± 9.4	55.4±6 .1	61.7± 12.0	47.4± 9.9	-	-	-	50.6±9 .2	-	63.3± 7.3	-	49.8± 9.5

PCI, %	-	100	48.5	100	-	100	100	-	-	-	100	100	100	-	-
Anterior MI, %	-	44.8	-	50.5	-	-	57.9	-	-	-	-	53.1	-	-	-
MVD, %	67.6	-	-	-	-	-	29.2	-	-	-	-	46.4	-	-	-
GPI use, %	-	-	-	46	-	-	44.7	-	-	-	-	-	-	-	-

(Continued) Supplementary Table 3. Baseline features of the included studies.

Study, year	Chen Xinsen, 2020	Adali, 2022	Liang, 2023	Pedersen, 2023	Toprak 2023
Country	China	Turkey	China	Denmark	Turkey
Study design	Retrospective cohort	Retrospective cohort	Retrospective cohort	Prospective cohort	Retrospective cohort
Follow-up, months	-	31.5	12	37.2	1
Sample size, n	524	189	296	900	1202

Diagnosis	STEMI patients treated with PCI	Stable CAD patients	NST-ACS patients	Stable CAD patients	STEMI patients treated with PCI
Mean age, years	58.9±9.1	68.2±10.7	61.4±6.9	65±4	59.9±11.5
Males, %	57.1	81.4	69.9	78	69.2
Hypertension, %	64.9	-	48.3	-	66.3
Diabetes mellitus, %	44.7	-	20.3	28	34.4
Dyslipidemia, %	58.2	8.9	-	90	37.6
Smoking, %	55.2	21.1	50.9	22	70.5
Previous MI, %	-	46	-	88	-
Family history of CAD, %		8.5	-	-	9
History of PCI, %	-	-	-	-	-
BMI, kg/m ²	-	-	26.6±2.8	27±8	26.5±2
Baseline SBP, mmHg	-	127.6±17.8	-	-	134.1±19

Glucose, mg/dl	174.4±99.6	-	113.51±30. 63	-	117±36
Cholesterol, mg/dl	160.8±32.2	-		-	175.9±44.5
LDL-C, mg/dl	94.8±23.8	-	92.7±32	-	107.1±36
HDL-C, mg/dl	37.71±7.64	-	51.35±21.6 2	-	34.3±7.5
Fasting triglycerides,mg/dl	150.29±78	-	159.29	-	151.2±79.9
Creatinine, mg/dl	-	-	0.8±0.5	0.93±0.32	0.8 [0.7-1.0]
WBC, 10 ⁹ /l	-	-	7.9±3.3	7.1±2	8.0±3.8
Hemoglobin, g/l	229±65.4	-	-	8.8±0.8	136±17
Platelet count, 10 ⁹ /l	240.5±63.6	-	196.6±17.6	233±58	247.7±70.6
MPV, fl	-	-	-	-	-
EF, %	56.6±9.7	46.3±12.4	-	-	50.4±13.7
PCI, %	-	-	-	-	100
Anterior MI, %	-	-	-	-	-

MVD, %	-	70.9	-	-	-
GPI use, %		-	-	-	-

Abbreviations: ACS, acute coronary syndrome; BMI, body mass index; CAD, coronary artery disease; EF, ejection fraction; GPI, glycoprotein inhibitor use; HDL-C, high-density lipoproteins; LDL-C, low-density lipoproteins; MI, myocardial infarction; MPV, mean platelet volume; MVD, multivessel disease; NST-ACS, non-ST-elevation acute coronary syndrome; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; STEMI, ST-elevation myocardial infarction; UA, unstable angina; WBC, white blood cells. Data are presented as mean ± standard deviation or as median (interquartile range)/ median.

Supplementary Table 4. Leave-one out sensitivity analyses.

Omitting this study - first author, year	ML estimation			REML estimation		
	Estimate [95% CI]	I ²	tau ²	Estimate [95% CI]	I ²	tau ²
All ischemic heart disease patients						
MPV as a continuous variable for long-term mortality with HR as an effect estimate						
Taglieri, 2011	1.30 [1.21-1.38]	37.84	0.00	1.30 [1.21-1.39]	47.44	0.00
Eisen ACS subgroup, 2013	1.32 [1.26-1.38]	0.01	0.00	1.32 [1.26-1.38]	0.01	0.00
Eisen SCAD subgroup, 2013	1.30 [1.21-1.39]	38.12	0.00	1.30 [1.21-1.40]	46.98	0.00
Lekston, 2014	1.26 [1.18-1.35]	15.32	0.00	1.27 [1.19-1.37]	28.85	0.00
Wasilewski, 2016	1.29 [1.20-1.37]	36.23	0.00	1.29 [1.20-1.38]	45.49	0.00
Yu, 2017	1.29 [1.21-1.38]	38.09	0.00	1.30 [1.21-1.39]	47.88	0.00
Tian, 2018	1.28 [1.21-1.35]	29.74	0.00	1.28 [1.21-1.35]	37.00	0.00
Jiang, 2019	1.29 [1.22-1.36]	35.07	0.00	1.29 [1.22-1.36]	43.15	0.00
Adali, 2022	1.29 [1.21-1.37]	35.62	0.00	1.29 [1.21-1.37]	44.17	0.00
MPV as a categorical variable for long-term mortality with HR as an effect estimate						
Taglieri, 2011	1.74 [1.07-2.84]	0.00	0.00	2.95 [0.55-15.67]	69.57	0.36
Tekbas, 2011	2.66 [0.38-18.66]	59.09	0.27	2.87 [0.41-20.13]	72.53	0.49
Akgul, 2013	1.68 [1.22-2.33]	0.01	0.00	1.68 [1.22-2.33]	0.00	0.00
Jiang, 2019	1.70 [1.12-2.58]	0.01	0.00	1.94 [0.50-7.44]	81.88	0.16
MPV as a continuous variable for long-term MACE with HR as an effect estimate						
Taglieri, 2011	1.15 [1.04-1.28]	94.78	0.02	1.16 [1.04-1.28]	95.29	0.02
Eisen ACS subgroup, 2013	1.16 [1.05-1.29]	94.04	0.02	1.16 [1.05-1.29]	94.61	0.02
Eisen SCAD subgroup, 2013	1.16 [1.05-1.29]	94.51	0.02	1.16 [1.05-1.29]	95.04	0.02

Lopez-Cuenca , 2012	1.15 [1.04-1.27]	94.56	0.02	1.15 [1.04-1.27]	95.11	0.02
Wan, 2014	1.16 [1.05-1.29]	90.85	0.02	1.16 [1.05-1.29]	91.70	0.02
Siller-Matula, 2014	1.17 [1.05-1.29]	94.61	0.02	1.17 [1.06-1.29]	95.15	0.02
Wasilewski, 2016	1.16 [1.05-1.29]	94.80	0.02	1.16 [1.05-1.29]	95.31	0.02
Yu, 2017	1.15 [1.04-1.27]	94.46	0.02	1.15 [1.04-1.27]	95.03	0.02
Tian, 2018	1.14 [1.03-1.25]	93.44	0.02	1.14 [1.03-1.25]	94.19	0.02
Niu, 2018	1.12 [1.04-1.22]	90.65	0.01	1.13 [1.04-1.22]	91.69	0.01
Wada, 2018	1.18 [1.08-1.28]	91.15	0.01	1.18 [1.08-1.29]	92.28	0.01
Navarta, 2019	1.17 [1.06-1.29]	91.02	0.02	1.17 [1.06-1.30]	91.89	0.02
Chen Xinsen, 2020	1.15 [1.04-1.27]	94.50	0.02	1.15 [1.04-1.27]	95.06	0.02
Pedersen, 2023	1.17 [1.07-1.29]	94.04	0.02	1.17 [1.07-1.29]	94.62	0.02

MPV as a categorized variable for long-term MACE with HR as an effect estimate

Taglieri, 2011	2.23 [1.36-3.65]	86.05	0.00	2.25 [1.37-3.70]	87.52	0.00
Dogan, 2012	2.21 [1.34-3.63]	87.51	0.01	2.23 [1.35-3.68]	88.85	0.01
Lopez-Cuenca, 2012	2.17 [1.32-3.58]	88.25	0.01	2.20 [1.33-3.63]	89.55	0.01
Fabregat-Andres, 2013	2.05 [1.27-3.33]	87.74	0.01	2.08 [1.27-3.38]	89.13	0.01
Choi, 2014	2.02 [1.29-3.15]	86.97	0.01	2.03 [1.30-3.17]	88.31	0.01
Seo, 2014	1.98 [1.23-3.17]	86.47	0.01	2.00 [1.24-3.23]	88.06	0.01
Navarta, 2015	1.84 [1.22-2.78]	82.14	0.01	1.87 [1.23-2.83]	84.1	0.01
Niu, 2018	2.05 [1.25-3.37]	87.19	0.01	2.07 [1.26-3.42]	88.66	0.01
Wada, 2018	2.31 [1.54-3.46]	76.47	0.00	2.34 [1.56-3.52]	79.34	0.00
Chang, 2019	2.25 [1.38-3.67]	84.88	0.00	2.27 [1.39-3.71]	86.45	0.00
Navarta , 2019	2.02 [1.25-3.26]	87.27	0.01	2.04 [1.26-3.31]	88.73	0.01
Nozari, 2019	2.19 [1.33-3.60]	88.00	0.01	2.21 [1.34-3.66]	89.30	0.01

MPV as a categorized variable for in-hospital mortality with OR as an effect estimate

Tekbas, 2011	1.48 [0.82-2.65]	0.00	0.10	1.51 [0.77-2.97]	8.19	0.12
--------------	------------------	------	------	------------------	------	------

Ranjith, 2015	1.74 [0.88-3.44]	31.97	0.07	1.78 [0.84-3.75]	58.83	0.08
Monteiro Junior , 2018	1.66 [0.97-2.85]	27.21	0.06	1.65 [0.97-2.82]	49.86	0.06
Satiroglu, 2019	2.01 [1.36-2.97]	0.00	0.02	2.01 [1.36 2.97]	0.00	0.02

MPV as a categorized variable for in-hospital MACE with OR as an effect estimate

Osuna, 1998	1.88 [0.94-3.75]	87.95	0.07	2.03 [0.95-4.36]	92.64	0.06
Vakili, 2009	1.55 [0.89-2.69]	81.33	0.10	1.70 [0.87-3.32]	90.58	0.10
Akpek, 2011	1.84 [0.93-3.62]	89.97	0.07	2.01 [0.94-4.29]	94.17	0.07
Liu, 2014	1.87 [0.93-3.78]	87.02	0.07	2.03 [0.93-4.40]	92.02	0.07
Machado, 2018	1.60 [1.15-2.21]	0.00	0.01	1.83 [1.10-3.06]	58.59	0.03
Garlobo, 2019	1.50 [1.04-2.17]	77.68	0.04	1.53 [1.05-2.24]	82.10	0.03
Vogiatzis, 2019	1.56 [0.95-2.55]	81.68	0.07	1.61 [0.95-2.75]	86.71	0.07
Chen, 2020	1.63 [0.87-3.04]	85.38	0.10	1.85 [0.87-3.95]	93.52	0.09

Patients treated with percutaneous coronary intervention

Eisen ACS, 2013	1.33 [1.26 1.40]	0.11	0.00	1.33 [1.26 1.40]	0.03	0.00
Eisen SCAD, 2013	1.30 [1.18 1.44]	48.25	0.00	1.31 [1.18 1.45]	59.48	0.00
Lekston, 2014	1.27 [1.16 1.39]	25.29	0.00	1.28 [1.16 1.42]	44.55	0.00
Wasilewski, 2016	1.29 [1.18 1.41]	46.11	0.00	1.29 [1.18 1.42]	58.16	0.00
Yu, 2017	1.30 [1.18 1.42]	48.64	0.00	1.30 [1.18 1.44]	61.16	0.00
Tian, 2018	1.28 [1.19 1.37]	37.58	0.00	1.28 [1.19 1.37]	47.02	0.00
Jiang, 2019	1.29 [1.20 1.39]	44.35	0.00	1.29 [1.20 1.39]	54.46	0.00

Patients with acute coronary syndrome

Taglieri, 2011	1.30 [1.17 1.43]	51.97	0.00	1.30 [1.17 1.44]	62.86	0.00
Eisen ACS, 2013	1.33 [1.26 1.41]	0.11	0.00	1.33 [1.26 1.41]	0.11	0.00
Lekston, 2014	1.26 [1.13 1.40]	24.81	0.00	1.27 [1.14 1.42]	42.72	0.00

Wasilewski, 2016	1.28 [1.16 1.42]	50.70	0.00	1.29 [1.16 1.43]	61.76	0.00
Yu, 2017	1.29 [1.16 1.43]	52.61	0.00	1.30 [1.16 1.44]	63.82	0.00
Tian, 2018	1.27 [1.18 1.37]	42.12	0.00	1.27 [1.18 1.36]	51.18	0.00

MPV as a continuous variable for long-term MACE with HR as an effect estimate

Taglieri, 2011	1.22 [1.10 1.37]	93.96	0.00	1.23 [1.10 1.37]	94.77	0.00
Eisen ACS, 2013	1.24 [1.11 1.37]	92.30	0.00	1.24 [1.12 1.38]	93.29	0.00
Wasilewski, 2016	1.23 [1.11 1.37]	93.79	0.00	1.24 [1.11 1.37]	94.60	0.00
Yu, 2017	1.21 [1.09 1.35]	93.50	0.00	1.21 [1.09 1.35]	94.44	0.00
Tian, 2018	1.19 [1.08 1.32]	91.71	0.00	1.20 [1.08 1.32]	93.14	0.00
Lopez-Cuenca , 2012	1.22 [1.09 1.35]	93.52	0.00	1.22 [1.10 1.35]	94.43	0.00
Wan, 2014	1.23 [1.11 1.37]	87.26	0.00	1.24 [1.11 1.38]	88.78	0.00
Niu, 2018	1.17 [1.09 1.26]	86.25	0.00	1.17 [1.09 1.26]	88.34	0.00
Navarta , 2019	1.24 [1.13 1.37]	84.01	0.00	1.25 [1.13 1.37]	86.28	0.00
Liang, 2023	1.22 [1.10 1.36]	93.87	0.00	1.22 [1.10 1.36]	94.73	0.00
Chen Xinsen, 2020	1.21 [1.09 1.35]	93.46	0.00	1.22 [1.09 1.35]	94.39	0.00

MPV as a categorical variable for long-term MACE with HR as an effect estimate

Taglieri, 2011	2.35 [1.46 3.78]	73.09	0.00	2.39 [1.47 3.88]	77.12	0.00
Lopez-Cuenca , 2012	2.27 [1.39 3.70]	79.39	0.00	2.32 [1.41 3.81]	82.70	0.00
Niu, 2018	2.09 [1.28 3.40]	75.92	0.01	2.14 [1.30 3.53]	80.36	0.01
Navarta , 2019	2.06 [1.30 3.26]	75.62	0.01	2.10 [1.32 3.36]	80.00	0.01
Dogan, 2012	2.32 [1.43 3.77]	77.30	0.00	2.36 [1.44 3.87]	80.77	0.00
Fabregat-Andres, 2013	2.11 [1.32 3.37]	77.40	0.01	2.15 [1.33 3.48]	81.33	0.01
Choi, 2014	2.08 [1.37 3.18]	75.80	0.00	2.11 [1.38 3.24]	79.56	0.00
Navarta, 2015	1.79 [1.30 2.47]	49.32	0.00	1.83 [1.31 2.54]	57.55	0.00
Chang, 2019	2.36 [1.48 3.76]	69.35	0.00	2.41 [1.50 3.86]	74.06	0.00

Nozari, 2019	2.29 [1.41 3.74]	78.74	0.00	2.34 [1.42 3.84]	82.07	0.00
MPV as a categorized variable for in-hospital mortality with OR as an effect estimate						
Tekbas, 2011	1.48 [0.82 2.65]	0.00	0.10	1.51 [0.77 2.97]	8.19	0.12
Ranjith, 2015	1.74 [0.88 3.44]	31.97	0.07	1.78 [0.84 3.75]	58.83	0.08
Monteiro Junior , 2018	1.66 [0.97 2.85]	27.21	0.06	1.65 [0.97 2.82]	49.86	0.06
Satiroglu, 2019	2.01 [1.36 2.97]	0.00	0.02	2.01 [1.36 2.97]	0.00	0.02
MPV as a categorized variable for in-hospital MACE with OR as an effect estimate						
Osuna, 1998	1.88 [0.94 3.75]	87.95	0.07	2.03 [0.95 4.36]	92.6	0.06
Vakili, 2009	1.55 [0.89 2.69]	81.33	0.10	1.70 [0.87 3.32]	90.58	0.10
Akpek, 2011	1.84 [0.93 3.62]	89.97	0.07	2.01 [0.94 4.29]	94.17	0.07
Liu, 2014	1.87 [0.93 3.78]	87.02	0.07	2.03 [0.93 4.40]	92.02	0.07
Machado, 2018	1.60 [1.15 2.21]	0.00	0.01	1.83 [1.10 3.06]	0.07	0.03
Garlobo, 2019	1.50 [1.04 2.17]	77.68	0.04	1.53 [1.05 2.24]	82.10	0.03
Vogiatzis, 2019	1.56 [0.95 2.55]	81.68	0.07	1.61 [0.95 2.75]	86.71	0.07
Chen, 2020	1.63 [0.87 3.04]	85.38	0.10	1.85 [0.87 3.95]	93.52	0.09
Patients with stable coronary artery disease						
MPV as a continuous variable for long-term mortality with HR as an effect estimate						
Eisen SCAD, 2013	1.52 [0.23 10.09]	0.01	0.22	1.53 [0.21 11.35]	8.47	0.23
Jiang, 2019	1.28 [0.92 1.77]	0.00	0.07	1.28 [0.92 1.77]	0.00	0.07
Adali, 2022	1.28 [0.61 2.67]	0.00	0.15	1.45 [0.09 24.3]	52.96	0.34

Abbreviations: ML, maximum likelihood; REML, restricted maximum likelihood; CI, confidence interval; MPV, mean platelet volume; HR, hazard ratio; MACE, major adverse cardiovascular events.

Supplementary Table 5. Subgroup analyses.

Subgroups	Estimate	P value for subgroup difference
All ischemic heart disease patients		


MPV as a continuous variable for long-term mortality with HR as an effect estimate			
SCAD	1.29 [1.07-1.55] - 3 studies	0.985	
ACS	1.29 [1.19-1.39] - 9 studies		
MPV as a continuous variable for long-term MACE with HR as an effect estimate			
SCAD	0.98 [0.66-1.45] - 3 studies	0.030	
ACS	1.22 [1.11-1.34] - 11 studies		
MPV as a categorical variable for long-term MACE with HR as an effect estimate			
SCAD	0.70 [0.54-0.91] - 1 study	<.001	
ACS	2.17 [1.41-3.32] - 10 study		
All percutaneous coronary intervention patients			
MPV as a continuous variable for long-term mortality with HR as an effect estimate			
SCAD	1.28 [0.61-2.67] - 2 studies	0.833	
ACS	1.30 [1.17-1.43] - 5 studies		
MPV as a continuous variable for long-term MACE with HR as an effect estimate			
SCAD	1.00 [0.17-5.88] - 2 studies	0.177	
ACS	1.22 [1.05-1.42] - 5 studies		
MPV as a categorical variable for long-term MACE with HR as an effect estimate			
SCAD	0.70 [0.54-0.91] - 1 study	<.001	
ACS	2.81 [1.03-7.67] - 4 studies		
Patients with acute coronary syndrome			
MPV as a continuous variable for long-term mortality with HR as an effect estimate			
STEMI	1.35 [0.90-2.04] - 2 studies	0.127	
NST-ACS	1.27 [1.15-1.41] - 3 studies		
MPV as a continuous variable for long-term MACE with HR as an effect estimate			
STEMI	1.41 [1.00-1.97] - 2 studies	<.001	
NST-ACS	1.19 [1.11-1.28] - 5 studies		
MPV as a continuous variable for long-term MACE with HR as an effect estimate			
SCAD	3.35 [1.12-10.05] - 1 study	0.152	
ACS	1.50 [1.32-1.69] - 4 studies		

Supplementary Table 6. Meta-regression analysis.


	All IHD: HR, long-term mortality, continuous			All IHD: HR, long-term MACE, continuous			All IHD: HR, long-term MACE, categorical			ACS: HR, long-term MACE, continuous			ACS: HR, long-term MACE, categorical		
	N	estim ate	p valu e	N	estim ate	p valu e	N	estim ate	p valu e	N	estim ate	p valu e	N	estim ate	p valu e
Analyser	9	-0.11, -0. 01	0.49-0. .91	15		0.27-0. 10	12		0.39, 0.53	11		0,37-0. 99	10	-0.51	0.087 (for Advia)
Publication year	9	0.02	0.002	15	-0.0025	0.83	12	-0.0231	0.7071	11	0.0088	0.4674	10	0.0198	0.693
Study design	9	-0.49	0.16	15	0.16	0.02	12	0.3418	0.3552	11	0.1334	0.0717	10	0.0007	0.9983
Sample	9	-0.00	0.003	15	-0.0000	0.803	12	-0.0002	0.00831	11	0.0000	0.8063	10	-0.0001	0.4456
ACS	9	-0.0001	0.807	15	0.0022	0.0079	12	0.0096	0.00567	-	-	-	-	-	-
STEMI	8	0.0005	0.106	12	0.0028	0.02	10	0.0121	0.01549	9	0.0020	0.0923	9	0.0092	0.0973
NST-ACS	8	-0.0005	0.307	12	0.0008	0.49	10	0.0029	0.5719	9	-0.0020	0.0924	9	-0.0092	0.0973
SCAD	9	0.0001	0.807	15	-0.0022	0.0079	12	-0.0096	0.00567	-	-	-	-	-	-
PCI	8	0.0015	0.508	9	-0.0014	0.75	8	-0.0085	0.5105	6	0.0007	0.8410	6	-0.0051	0.691
Age	9	-0.01	0.03	15	-0.0121	0.11	12	0.0081	0.8161	11	-0.0110	0.0753	10	0.0087	0.7568
Males	9	-0.0076	0.005	15	-0.001	0.84	12	-0.0553	0.0010	11	0.0089	0.0790	10	-0.0352	0.1199

hypertension	8	-0.0 048	0.0 6	14	-0.0 06	0.0 161	12	-0.0 05	0.7 575	11	-0.0 047	0.0 702	10	0.0 055	0.6 875
diabetes	8	0.0 012	0.7 1	15	-0.0 05	0.2 624	12	-0.0 392	0.0 143	11	-0.0 002	0.9 672	10	-0.0 253	0.0 763
dyslipidemia	6	-0.0 002	0.9 2	11	-0.0 027	0.4 994	12	-0.0 22	0.0 649	8	0.0 072	0.0 623	10	-0.0 054	0.7 408
smoking	8	0.0 01	0.7 2	15	0.00 78	0.0 002	12	0.0 106	0.4 510	11	0.0 068	0.0 017	10	-0.0 038	0.7 738
prior MI	7	-0.0 017	0.4 8	9	-0.0 05	0.0 213	5	-0.0 281	0.0 573	7	-0.0 050	0.2 637	5	-0.0 281	0.0 573
creatinine	7	0.2 9	0.1 1	11	-0.1 824	0.6 245	11	-0.9 910	0.4 910	9	-0.2 979	0.4 387	10	-1.7 902	0.1 42
WBC	6	0.0 06	0.6 7	10	0.09 46	0.0 577	8	0.1 632	0.3 182	8	-0.0 461	0.5 801	7	-0.1 669	0.3 801
platelet	6	-0.0 03	0.0 03	13	-0.0 036	0.1 328	10	-0.0 025	0.7 711	9	-0.0 037	0.0 782	9	-0.0 078	0.2 122
BMI	3	0.0 005	0.9 9	6	-0.0 315	0.5 519	5	-0.0 503	0.7 893	3	-0.0 887	0.0 005	3	-0.0 873	0.4 793
SBP	6	-0.0 06	0.2 5	6	-0.0 047	0.3 554	4	0.0 134	0.7 199	6	-0.0 047	0.3 554	3	0.0 168	0.6 771
Gluco-sae	3	-0.0 004	0.8 7	7	0.00 21	0.5 53	6	0.0 559	0.0 446	6	0.0 005	0.8 719	4	0.0 365	0.0 559
hemoglobin	8	0.0 05	0.1 1	12	0.00 29	0.1 158	9	0.0 503	0.0 116	8	0.0 012	0.5 558	8	0.0 368	0.0 024
EF	6	0.0 02	0.6 7	7	-0.0 08	0.5 613	7	-0.0 300	0.6 268	6	0.0 058	0.5 963	5	0.1 295	0.0 512
MVD	7	-0.0 02	0.0 2	5	0.00 29	0.5 911	3	-0.0 472	0.0 191	3	-0.0 037	0.2 075	-	-	-


Supplementary Figures.




Supplementary Figure S1. All ischemic heart disease patients. Additional analyses for long-term mortality with MPV as a continuous variable and hazard ratios as effect estimates.
A, funnel plot for publication bias assessment; **B**, a trim and fill method for publication bias assessment; **C**, a Q-Q plot for ML estimation; **D**, cumulative meta-analysis for ML estimation.
Abbreviations: CI, confidence interval; ML, maximum likelihood; MPV, mean platelet volume.



Supplementary Figure S2. All ischemic heart disease patients. Analyses for long-term mortality with MPV treated as a categorical variable and hazard ratios as effect estimates.
Abbreviations: CI, confidence interval; PI, prediction interval; RE, random effects; ML, maximum likelihood; REML, restricted maximum likelihood; MPV, mean platelet volume.




Supplementary Figure S3. All ischemic heart disease patients. Analyses for long-term major cardiovascular events with MPV treated as a continuous variable and hazard ratios as effect estimates. Abbreviations: CI, confidence interval; PI, prediction interval; RE, random effects; ML, maximum likelihood; REML, restricted maximum likelihood; MPV, mean platelet volume.




Supplementary Figure S4. All ischemic heart disease patients. Additional analyses for long-term major cardiovascular events with MPV treated as a continuous variable and hazard ratios as effect estimates. A, funnel plot for publication bias assessment; B, a trim and fill method for publication bias assessment; C, a Q-Q plot for ML estimation; D, cumulative meta-analysis for ML estimation.

Abbreviations: CI, confidence interval; ML, maximum likelihood; MPV, mean platelet volume.




Supplementary Figure S5. All ischemic heart disease patients. Analyses for long-term major cardiovascular events with MPV treated as a categorical variable and hazard ratios as effect estimates.

Abbreviations: CI, confidence interval; PI, prediction interval; RE, random effects; ML, maximum likelihood; REML, restricted maximum likelihood; MPV, mean platelet volume.




Supplementary Figure S6. All ischemic heart disease patients. Additional analyses for long-term major cardiovascular events with MPV treated as a categorical variable and hazard ratios as effect estimates. A, funnel plot for publication bias assessment; B, a trim and fill method for publication bias assessment; C, a Q-Q plot for ML estimation; D, cumulative meta-analysis for ML estimation.

Abbreviations: CI, confidence interval; ML, maximum likelihood; MPV, mean platelet volume.




Supplementary Figure S7. All ischemic heart disease patients. Analyses for long-term major cardiovascular events with MPV treated as a categorical variable and odds ratios as effect estimates.

Abbreviations: CI, confidence interval; PI, prediction interval; RE, random effects; ML, maximum likelihood; REML, restricted maximum likelihood; MPV, mean platelet volume.




Supplementary Figure S8. All ischemic heart disease patients. Analyses for long-term mortality with MPV treated as a categorical variable and odds ratios as effect estimates.

Abbreviations: CI, confidence interval; PI, prediction interval; RE, random effects; ML, maximum likelihood; REML, restricted maximum likelihood; MPV, mean platelet volume.




Supplementary Figure S9. All ischemic heart disease patients. Analyses for one-month mortality with MPV treated as a continuous variable and hazard ratios as effect estimates.

Abbreviations: CI, confidence interval; PI, prediction interval; RE, random effects; ML, maximum likelihood; REML, restricted maximum likelihood; MPV, mean platelet volume.




Supplementary Figure S10. All ischemic heart disease patients. Analyses for one-month mortality with MPV treated as a categorical variable and odds ratios as effect estimates.

Abbreviations: CI, confidence interval; PI, prediction interval; RE, random effects; ML, maximum likelihood; REML, restricted maximum likelihood; MPV, mean platelet volume.




Supplementary Figure S11. All ischemic heart disease patients. Analyses for one-month major adverse cardiovascular events with MPV treated as a categorical variable and odds ratios as effect estimates.

Abbreviations: CI, confidence interval; PI, prediction interval; RE, random effects; ML, maximum likelihood; REML, restricted maximum likelihood; MPV, mean platelet volume.




Supplementary Figure S12. All ischemic heart disease patients. Analyses for inhospital mortality with MPV treated as a categorical variable and odds ratios as effect estimates.

Abbreviations: CI, confidence interval; PI, prediction interval; RE, random effects; ML, maximum likelihood; REML, restricted maximum likelihood; MPV, mean platelet volume.




Supplementary Figure S13. All ischemic heart disease patients. Analyses for inhospital major adverse cardiovascular events with MPV treated as a categorical variable and odds ratios as effect estimates.

Abbreviations: CI, confidence interval; PI, prediction interval; RE, random effects; ML, maximum likelihood; REML, restricted maximum likelihood; MPV, mean platelet volume.




Supplementary Figure S14. Patients treated with percutaneous coronary intervention. Additional analyses for long-term mortality with MPV treated as a continuous variable and hazard ratios as effect estimates. A, funnel plot for publication bias assessment; B, a trim and fill method for publication bias assessment; C, a Q-Q plot for ML estimation; D, cumulative meta-analysis for ML estimation.

Abbreviations: CI, confidence interval; ML, maximum likelihood; MPV, mean platelet volume.




Supplementary Figure S15. Patients treated with percutaneous coronary intervention. Analyses for long-term major adverse cardiovascular events with MPV treated as a continuous variable and hazard ratios as effect estimates.

Abbreviations: CI, confidence interval; PI, prediction interval; RE, random effects; ML, maximum likelihood; REML, restricted maximum likelihood; MPV, mean platelet volume.




Supplementary Figure S16. Patients treated with percutaneous coronary intervention. Analyses for long-term major adverse cardiovascular events with MPV treated as a categorical variable and hazard ratios as effect estimates.

Abbreviations: CI, confidence interval; PI, prediction interval; RE, random effects; ML, maximum likelihood; REML, restricted maximum likelihood; MPV, mean platelet volume.




Supplementary Figure S17. Patients treated with percutaneous coronary intervention. Analyses for long-term major adverse cardiovascular events with MPV treated as a categorical variable and odds ratios as effect estimates.

Abbreviations: CI, confidence interval; PI, prediction interval; RE, random effects; ML, maximum likelihood; REML, restricted maximum likelihood; MPV, mean platelet volume.




Supplementary Figure S18. Patients treated with percutaneous coronary intervention. Analyses for one-month mortality with MPV treated as a continuous variable and hazard ratios as effect estimates.

Abbreviations: CI, confidence interval; PI, prediction interval; RE, random effects; ML, maximum likelihood; REML, restricted maximum likelihood; MPV, mean platelet volume.




Supplementary Figure S19. Patients treated with percutaneous coronary intervention. Analyses for inhospital major adverse cardiovascular events with MPV treated as a categorical variable and odds ratios as effect estimates.

Abbreviations: CI, confidence interval; PI, prediction interval; RE, random effects; ML, maximum likelihood; REML, restricted maximum likelihood; MPV, mean platelet volume.




Supplementary Figure S20. Patients with acute coronary syndrome. Analyses for long-term mortality with MPV treated as a continuous variable and hazard ratios as effect estimates.

Abbreviations: CI, confidence interval; PI, prediction interval; RE, random effects; ML, maximum likelihood; REML, restricted maximum likelihood; MPV, mean platelet volume.




Supplementary Figure S21. Patients with acute coronary syndrome. Additional analyses for long-term mortality with MPV treated as a continuous variable and hazard ratios as effect estimates. A, funnel plot for publication bias assessment; B, a trim and fill method for publication bias assessment; C, a Q-Q plot for ML estimation; D, cumulative meta-analysis for ML estimation.

Abbreviations: CI, confidence interval; ML, maximum likelihood; MPV, mean platelet volume.




Supplementary Figure S22. Patients with acute coronary syndrome. Analyses for long-term mortality with MPV treated as a categorical variable and hazard ratios as effect estimates.


Abbreviations: CI, confidence interval; PI, prediction interval; RE, random effects; ML, maximum likelihood; REML, restricted maximum likelihood; MPV, mean platelet volume.




Supplementary Figure S23. Patients with acute coronary syndrome. Analyses for long-term major adverse cardiovascular events with MPV treated as a continuous variable and hazard ratios as effect estimates. Abbreviations: CI, confidence interval; PI, prediction interval; RE, random effects; ML, maximum likelihood; REML, restricted maximum likelihood; MPV, mean platelet volume.




Supplementary Figure S24. Patients with acute coronary syndrome. Additional analyses for long-term major adverse cardiovascular events with MPV treated as a continuous variable and hazard ratios as effect estimates. A, funnel plot for publication bias assessment; B, a trim and fill method for publication bias assessment; C, a Q-Q plot for ML estimation; D, cumulative meta-analysis for ML estimation. Abbreviations: CI, confidence interval; ML, maximum likelihood; MPV, mean platelet volume.




Supplementary Figure S25. Patients with acute coronary syndrome. Analyses for long-term major adverse cardiovascular events with MPV treated as a categorical variable and hazard ratios as effect estimates. Abbreviations: CI, confidence interval; PI, prediction interval; RE, random effects; ML, maximum likelihood; REML, restricted maximum likelihood; MPV, mean platelet volume.




Supplementary Figure S26. Patients with acute coronary syndrome. Additional analyses for long-term major adverse cardiovascular events with MPV treated as a categorical variable and hazard ratios as effect estimates. A, funnel plot for publication bias assessment; B, a trim and fill method for publication bias assessment; C, a Q-Q plot for ML estimation; D, cumulative meta-analysis for ML estimation. Abbreviations: CI, confidence interval; ML, maximum likelihood; MPV, mean platelet volume.




Supplementary Figure S27. Patients with acute coronary syndrome. Analyses for long-term major adverse cardiovascular events with MPV treated as a categorical variable and odds ratios as effect estimates. Abbreviations: CI, confidence interval; PI, prediction interval; RE, random effects; ML, maximum likelihood; REML, restricted maximum likelihood; MPV, mean platelet volume.



Supplementary Figure S28. Patients with acute coronary syndrome. Analyses for one-month mortality with MPV treated as a continuous variable and hazard ratios as effect estimates.
Abbreviations: CI, confidence interval; PI, prediction interval; RE, random effects; ML, maximum likelihood; REML, restricted maximum likelihood; MPV, mean platelet volume.




Supplementary Figure S29. Patients with acute coronary syndrome. Analyses for one-month mortality with MPV treated as a categorical variable and odds ratios as effect estimates.
Abbreviations: CI, confidence interval; PI, prediction interval; RE, random effects; ML, maximum likelihood; REML, restricted maximum likelihood; MPV, mean platelet volume.




Supplementary Figure S30. Patients with acute coronary syndrome. Analyses for inhospital mortality with MPV treated as a categorical variable and odds ratios as effect estimates.


Abbreviations: CI, confidence interval; PI, prediction interval; RE, random effects; ML, maximum likelihood; REML, restricted maximum likelihood; MPV, mean platelet volume.




Supplementary Figure S31. Patients with acute coronary syndrome. Analyses for inhospital major adverse cardiovascular events with MPV treated as a categorical variable and odds ratios as effect estimates. Abbreviations: CI, confidence interval; PI, prediction interval; RE, random effects; ML, maximum likelihood; REML, restricted maximum likelihood; MPV, mean platelet volume.




Supplementary Figure S32. Patients with acute coronary syndrome. Additional analyses for inhospital major adverse cardiovascular events with MPV treated as a categorical variable and odds ratios as effect estimates. A, funnel plot for publication bias assessment; B, a trim and fill method for publication bias assessment; C, a Q-Q plot for ML estimation; D, cumulative meta-analysis for ML estimation. Abbreviations: CI, confidence interval; ML, maximum likelihood; MPV, mean platelet volume.



Supplementary Figure S33. Patients with stable coronary artery disease. Analyses for long-term mortality with MPV treated as a continuous variable and hazard ratios as effect estimates. Abbreviations: CI, confidence interval; PI, prediction interval; RE, random effects; ML, maximum likelihood; REML, restricted maximum likelihood; MPV, mean platelet volume.



Supplementary Figure S34. Patients with stable coronary artery disease. Analyses for long-term major adverse cardiovascular events with MPV treated as a continuous variable and hazard ratios as effect estimates. Abbreviations: CI, confidence interval; PI, prediction interval; RE, random effects; ML, maximum likelihood; REML, restricted maximum likelihood; MPV, mean platelet volume.



Supplementary Figure S35. Patients with stable coronary artery disease. Analyses for long-term major adverse cardiovascular events with MPV treated as a categorical variable and odds ratios as effect estimates. Abbreviations: CI, confidence interval; PI, prediction interval; RE, random effects; ML, maximum likelihood; REML, restricted maximum likelihood; MPV, mean platelet volume.